Infliximab biosimilar linked to increased risk of uveitis fl
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This retrospective study measured the recurrence of inflammation after switching from the original infliximab (Remicade) to a biosimilar for noninfectious uveitis. Researchers assessed 17 patients with noninfectious uveitis who were switched from originator infliximab to biosimilar infliximab for nonmedical reasons. The main outcome measure was the frequency of inflammation, defined as new or worsening inflammatory activity on exam or imaging.

Patients experienced more flares after switching from originator to biosimilar infliximab. Of the 6 patients who flared after changing treatments, 4 did so within 90 days, suggesting that there may be some risk of inflammation associated with switching treatments. Three patients responded well and achieved quiescence with increased dosages of the biosimilar.

Patients changing from infliximab to biosimilar infliximab for uveitis should be closely observed, especially for the first 90 days. These patients tend to experience more flares after switching treatments but may achieve quiescence with increased biosimilar dosing.

Source: https://www.aao.org/editors-choice/infliximab-biosimilar-linked-to-increased-risk-of-
Like
Comment
Share